EWA
NAVB

Exencial Wealth Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Exencial Wealth Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,500
Closed -$19K – 170
2016
Q4 		$19K Buy
+1,500
New +$23.8K 0.01% 169

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Exencial Wealth Advisors's NAVB Position: Q1 2017 in Review

Exencial Wealth Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2017, closing a stake of 1,500 shares — an estimated $19K sold.

Exencial Wealth Advisors first reported a position in NAVB in Q4 2016 and held it in 1 quarter. The position peaked at $19K in Q4 2016. 52 funds tracked by Wall St. Rank hold NAVB as of Q1 2017.

  • Exencial Wealth Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2017 after selling out during the quarter.
  • Exencial Wealth Advisors sold 1,500 Navidea Biopharmaceuticals Inc. shares in Q1 2017, an estimated $19K.
  • Exencial Wealth Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2016 and held it in 1 quarter.
  • Exencial Wealth Advisors's Navidea Biopharmaceuticals Inc. position peaked at $19K in Q4 2016.
  • 52 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2017.

Based on Exencial Wealth Advisors's 13F filing for Q1 2017, filed 26 Apr 2017.